SCHEMBL2357949

SCHEMBL2357949

CCn1c2c(c3ccccc31)CNCC2

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
KDM4E B2RXH2 2/20 0.52
RAB9A P51151 1/20 0.52
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
SIRT2 Q8IXJ6 3/20 0.48
SIRT1 Q96EB6 1/20 0.46
HTR5A P47898 1/20 0.45
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
ALDH1A1 P00352 1/20 0.44
HTR6 P50406 1/20 0.43
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30873508 1.00 HDAC1 (0.55) HDAC1HDAC6KDM4ERAB9AHTR2A
SCHEMBL9615137 0.88 HTR2A (0.55) HDAC1HDAC6KDM4ERAB9AHTR2A
Trifluoroacetic Acid SCHEMBL31078319 0.88 HDAC6 (0.53) HDAC1HDAC6KDM4ERAB9AHTR2A
Hydrochloric Acid SCHEMBL9696491 0.87 KDM4E (0.56) HDAC1HDAC6KDM4ERAB9AHTR2A
SCHEMBL176660 0.84 SIRT2 (0.66) HDAC1HDAC6KDM4ERAB9AHTR2A
SCHEMBL2192008 0.82 HDAC1 (0.56) HDAC1HDAC6KDM4EHTR2AHTR2C
SCHEMBL8025072 0.82 HDAC1 (0.69) HDAC1HDAC6CA1CA2ALDH1A1
SCHEMBL8106969 0.82 HDAC1 (0.53) HDAC1HDAC6KDM4EHTR2AHTR2C
SCHEMBL2187576 0.81 HDAC1 (0.55) HDAC1HDAC6KDM4EHTR2AHTR2C
SCHEMBL8100771 0.81 HDAC1 (0.52) HDAC1HDAC6KDM4EHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145887-B1 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF ALLA CHEM LLC (US) 2016-04-27 EP claimed
EP-2145887-A2 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF Alla Chem, LLC. (US) 2010-01-20 EP claimed
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2022-12-01 US disclosed
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2022-12-01 US disclosed
US-11420967-B2 Modified carbazoles as therapeutic agents UNIVERSITY OF WASHINGTON (US) 2022-08-23 US disclosed
EP-3807262-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS University of Washington (US) 2021-04-21 EP disclosed
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2021-04-01 US disclosed
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2021-04-01 US disclosed
US-20190233409-A1 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF IVACHTCHENKO ALEXANDRE VASILIEVICH (US) 2019-08-01 US disclosed
US-9655886-B2 Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof IVACHTCHENKO ALEXANDRE VASILIEVICH (US) 2017-05-23 US disclosed
US-20170000773-A1 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF IVACHTCHENKO ALEXANDRE VASILIEVICH (US) 2017-01-05 US disclosed
US-20130217703-A1 SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF ALLA CHEM, LLC (US) 2013-08-22 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
US-20100120792-A1 Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof ALLA CHEM, LLC 2010-05-13 US disclosed
EP-2145887-A2 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF Alla Chem, LLC. (US) 2010-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, TUBA1C HDAC1 95/4885HDAC6 8/4885KDM4E 3152/4885
US-20100120792-A1 Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof HTR3C, HTR3A, HTR6 HDAC1 3057/4885HDAC6 2532/4885KDM4E 4130/4885
US-20190233409-A1 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF ADORA3, HTR3C, TRPV3 HDAC1 1781/4885HDAC6 1928/4885KDM4E 3153/4885
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, TUBA1C HDAC1 95/4885HDAC6 8/4885KDM4E 3152/4885
US-20170000773-A1 SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF HTR6, HTR3C, HTR3B HDAC1 2589/4885HDAC6 1919/4885KDM4E 4105/4885
US-20130217703-A1 SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF HTR6, HTR3C, HTR3B HDAC1 2740/4885HDAC6 2694/4885KDM4E 3802/4885
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I HDAC1 265/4885HDAC6 287/4885KDM4E 816/4885
US-11420967-B2 Modified carbazoles as therapeutic agents TUBB3, TUBB1, TUBA1C HDAC1 95/4885HDAC6 8/4885KDM4E 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.